Antiphospholipid syndrome
The tests available to support the diagnosis of APS are:
EliA™ Cardiolipin IgG
(14-5529-01)
EliA Cardiolipin IgG is a diagnostically useful test with excellent specificity and sensitivity3
In order to minimise bias, the performance of the new EliA APS tests was evaluated in a study where each assay was compared to three commercial tests, using two different APS panels. Both panels of 50 and 51 APS patients (as mentioned above) were defined by different APS specialists. The resulting test performance is shown in the above figure (grey: Sensitivity in 51 APS patients, panel 1; blue: Sensitivity in 50 APS patients, panel 2; yellow: Specificity in 301 disease controls)
Cut-off/measuring range
| Negative | Equivocal | Positive | Measuring range | |
|---|---|---|---|---|
| EliA Cardiolipin IgG | <10 GPL-U/ml | 10-40 GPL-U/ml | >40 GPL-U/ml | 0.5-≥418 GPL-U/ml |
Coating
- Bovine cardiolipin antigen
Dilution
- 1:10
Sample material
- Serum, plasma (EDTA, citrate, heparin)
EliA™ Cardiolipin IgM
(14-5530-01)
EliA Cardiolipin IgM is a diagnostically useful test with excellent specificity and sensitivity3
In order to minimise bias, the performance of the new EliA APS tests was evaluated in a study where each assay was compared to three commercial tests, using two different APS panels. Both panels of 50 and 51 APS patients (as mentioned above) were defined by different APS specialists. The resulting test performance is shown in the above figure (grey: Sensitivity in 51 APS patients, panel 1; blue: Sensitivity in 50 APS patients, panel 2; yellow: Specificity in 301 disease controls)
Cut-off/measuring range
| Negative | Equivocal | Positive | Measuring range | |
|---|---|---|---|---|
| EliA Cardiolipin IgM | <10 MPL-U/ml | 10-40 MPL-U/ml | >40 MPL-U/ml | 0.8-≥472 MPL-U/ml |
Coating
- Bovine cardiolipin antigen
Dilution
- 1:10
Sample material
- Serum, plasma (EDTA, citrate, heparin)
EliA β2-glycoprotein I IgG
(14-5532-01)
EliA β2-glycoprotein I IgG is a diagnostically useful test with excellent specificity and sensitivity3
In order to minimise bias, the performance of the new EliA APS tests was evaluated in a study where each assay was compared to three commercial tests, using two different APS panels. Both panels of 50 and 51 APS patients (as mentioned above) were defined by different APS specialists. The resulting test performance is shown in the above figure (grey: Sensitivity in 51 APS patients, panel 1; blue: Sensitivity in 50 APS patients, panel 2; yellow: Specificity in 301 disease controls)
Cut-off/measuring range
| Negative | Equivocal | Positive | Measuring range | |
|---|---|---|---|---|
| EliA β2-glycoprotein I IgG | <7 GPL-U/ml | 7-10 GPL-U/ml | >10 GPL-U/ml | 0.6-≥532 U/ml |
Coating
- Human β2-Glycoprotein I antigen
Dilution
- 1:10
Sample material
- Serum, plasma (EDTA, citrate, heparin)
EliA β2-glycoprotein I IgM
(14-5533-01)
EliA β2-glycoprotein I IgM is a diagnostically useful test with excellent specificity and sensitivity3
In order to minimise bias, the performance of the new EliA APS tests was evaluated in a study where each assay was compared to three commercial tests, using two different APS panels. Both panels of 50 and 51 APS patients (as mentioned above) were defined by different APS specialists. The resulting test performance is shown in the above figure (grey: Sensitivity in 51 APS patients, panel 1; blue: Sensitivity in 50 APS patients, panel 2; yellow: Specificity in 301 disease controls)
Cut-off/measuring range
| Negative | Equivocal | Positive | Measuring range | |
|---|---|---|---|---|
| EliA β2-glycoprotein I IgM | <7 GPL-U/ml | 7-10 GPL-U/ml | >10 GPL-U/ml | 2.9-≥576 U/ml |
Coating
- Human β2-Glycoprotein I antigen
Dilution
- 1:50
Sample material
- Serum, plasma (EDTA, citrate, heparin)
Cut-off/measuring range, coating, dilution and sample material have been taken from respective Phadia 250 DFUs. The data is intended as a guide and should be treated accordingly. If you have any questions or uncertainty please contact your local service team or Laboratory Sales Representative.
- Saigal R, et al. J Assoc Physicians India 2010; 58: 176-184.
- Meroni LP, et al. Arthritis Res Ther 2014; 16: 209.
- Thermo Fisher Scientific. Internal Study.
- www.kvadigital.co.uk
